Azathramycin

• CAT Number: I004829
• CAS Number: 76801-85-9
• Molecular Formula: C37H70N2O12
• Molecular Weight: 734.96
• Purity: ≥95%
• Synonyms: (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,8,10,12,14-hexame
• Target: Bacterial
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one
• InChI: InChI=1S/C37H70N2O12/c1-14-26-37(10,45)30(41)23(6)38-18-19(2)16-35(8,44)32(51-34-28(40)25(39(11)12)15-20(3)47-34)21(4)29(22(5)33(43)49-26)50-27-17-36(9,46-13)31(42)24(7)48-27/h19-32,34,38,40-42,44-45H,14-18H2,1-13H3/t19-,20-,21+,22-,23-,24+,25+,26-,27+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
• InChIKey: HRKNNHYKWGYTEN-HOQMJRDDSA-N
• SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](NC[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O

Azathramycin（Cat No.:I004829）is a macrolide antibiotic related to azithromycin, known for its broad-spectrum antibacterial activity, particularly against respiratory pathogens and atypical bacteria. It works by inhibiting bacterial protein synthesis, binding to the 50S ribosomal subunit, effectively treating infections like pneumonia, bronchitis, and skin infections. Azathramycin offers a favorable pharmacokinetic profile with good tissue penetration and extended half-life, allowing for once-daily dosing, which enhances patient compliance. It is studied for its efficacy against drug-resistant bacteria and remains valuable in both outpatient and hospital infection management.

Reference

[1]. Noedl H, Krudsood S, Leowattana W, In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob Agents Chemother. 2007 Feb;51(2):651-6.
[2]. Hiwatashi Y, Maeda M, Fukushima H, Azithromycin suppresses proliferation, interleukin production and mitogen-activated protein kinases in human peripheral-blood mononuclear cells stimulated with bacterial superantigen. J Pharm Pharmacol. 2011 Oct;63(10):1320-6.
[3]. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol. 2000 Jan;39(1):45-50.